传统与新型β-内酰胺类对高产AmpC酶肠杆菌复合群和产气克雷伯菌的体外活性比较:多中心研究
结果显示哌拉西林/他唑巴坦耐药率高达82.4%,头孢吡肟达20.5%,而新型药物(包括头孢他啶/阿维巴坦等)敏感率≥99%。
要点
- 高产AmpC酶阴沟肠杆菌复合群和产气克雷伯菌对哌拉西林/他唑巴坦耐药率高达82.4%,对头孢吡肟达20.5%。
- 新型β-内酰胺类(如头孢他啶/阿维巴坦、头孢吡肟/他尼硼巴坦等)对上述菌株敏感率≥99%。
- 仅6株对至少一种新型药物敏感性降低,且未发现碳青霉烯酶或可解释的获得性β-内酰胺酶。
核心结论
- 高产AmpC酶阴沟肠杆菌复合群和产气克雷伯菌对传统β-内酰胺类(如哌拉西林/他唑巴坦、头孢吡肟)活性有限,新型β-内酰胺类敏感率≥99%,可作为有效替代方案。
研究设计与样本
- 对84株阴沟肠杆菌复合群和6株对至少一种新型药物敏感性降低的菌株进行全基因组测序。
主要发现
- 哌拉西林/他唑巴坦耐药率高达82.4%,头孢吡肟耐药率高达20.5%,碳青霉烯类活性不一。
- 新型药物(头孢他啶/阿维巴坦、头孢吡肟/他尼硼巴坦、亚胺培南/瑞来巴坦、美罗培南/法硼巴坦、头孢地尔)对两种菌的敏感率均≥99%。
- 仅6株对至少一种新型药物敏感性降低,未发现碳青霉烯酶或可解释的获得性β-内酰胺酶。
- 全基因组测序分析的阴沟肠杆菌复合群中,Enterobacter hormaechei占75%,ST型别高且blaACT等位基因多样。
关键数值与推荐
- 哌拉西林/他唑巴坦耐药率高达82.4%,头孢吡肟耐药率高达20.5%。
- 新型药物敏感率≥99%(两种菌均如此)。
- 仅6株对至少一种新型药物敏感性降低。
临床怎么用
- 临床实践中应识别高产AmpC酶表型,避免经验性使用哌拉西林/他唑巴坦或头孢吡肟。
- 对于高产AmpC酶阴沟肠杆菌复合群和产气克雷伯菌感染,可考虑选用新型β-内酰胺类(如头孢他啶/阿维巴坦等)作为有效替代。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antimicrobial resistance among Enterobacter cloacae complex and Klebsiella aerogenes is a growing clinical challenge, often driven by AmpC β-lactamase hyperproduction. This phenotype limits therapeutic options to cefepime or carbapenems. OBJECTIVES: To assess the in vitro activity of conventional β-lactams, such as cefepime, piperacillin/tazobactam or carbapenems, and new-generation agents, including ceftazidime/avibactam, cefepime/taniborbactam, imipenem/relebactam, meropenem/vaborbactam, and cefiderocol, against AmpC-hyperproducing E. cloacae complex and K. aerogenes. METHODS: A total of 314 clinical isolates (200 E. cloacae complex and 114 K. aerogenes) recovered between March and December 2024, from eight Spanish centres were tested by broth microdilution (EUCAST). AmpC hyperproduction was confirmed phenotypically and carbapenemase was screened phenotypically/molecularly. WGS was performed for (i) 84 E. cloacae complex isolates, and (ii) six isolates with reduced susceptibility to at least one novel agent. RESULTS: High resistance rates were observed for piperacillin/tazobactam (up to 82.4%) and cefepime (up to 20.5%), whereas carbapenems showed variable activity. New-generation agents exhibited excellent activity, with susceptibility rates ≥99% in both species. Resistance to at least one new agent was found in only six isolates. In the WGS-analysed E. cloacae complex subset, Enterobacter hormaechei predominated (75%) with high STs and blaACT allele diversity. In the six reduced-susceptibility isolates, no carbapenemase or explanatory acquired β-lactamase was found. CONCLUSIONS: Our findings underscore the need to take this phenotype into account in clinical practice and confirm the limited activity of conventional β-lactams against AmpC-hyperproducing E. cloacae complex and K. aerogenes, and support the use of newer agents as effective alternatives.
引用
- Rodríguez-Villodres Á, Rodríguez-Lozano J, Mir-Cros A, et al. Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. J Antimicrob Chemother. 2026. PMID: 41648989. doi:10.1093/jac/dkag034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。